U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Investigations, CTCAE

MedGen UID:
1643999
•Concept ID:
C4554620
•
Finding

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVInvestigations, CTCAE

Professional guidelines

PubMed

Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
Suzuki Y, Iwamoto T, Uno M, Hatono M, Kajiwara Y, Takahashi Y, Kochi M, Shien T, Kikawa Y, Uemura Y, Hagiwara Y, Yamamoto S, Taira N, Doihara H, Toyooka S
Breast Cancer 2023 Sep;30(5):856-868. Epub 2023 Jul 8 doi: 10.1007/s12282-023-01480-3. PMID: 37422608
Germline genetic biomarkers to stratify patients for personalized radiation treatment.
Deichaite I, Hopper A, Krockenberger L, Sears TJ, Sutton L, Ray X, Sharabi A, Navon A, Sanghvi P, Carter H, Moiseenko V
J Transl Med 2022 Aug 12;20(1):360. doi: 10.1186/s12967-022-03561-x. PMID: 35962345Free PMC Article
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC
Clin Trials 2021 Feb;18(1):104-114. Epub 2020 Dec 1 doi: 10.1177/1740774520975120. PMID: 33258687Free PMC Article

Recent clinical studies

Etiology

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.
Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ
Lancet Oncol 2022 Dec;23(12):1547-1557. Epub 2022 Nov 4 doi: 10.1016/S1470-2045(22)00638-6. PMID: 36343656Free PMC Article
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM, Steinberg RL, Martin AC, Richards J, Mott SL, Gellhaus PT, Nepple KG, O'Donnell MA, Packiam VT
J Urol 2022 Sep;208(3):589-599. Epub 2022 Jul 27 doi: 10.1097/JU.0000000000002740. PMID: 35892270
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V
Cochrane Database Syst Rev 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3. PMID: 33930176Free PMC Article
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC
Clin Trials 2021 Feb;18(1):104-114. Epub 2020 Dec 1 doi: 10.1177/1740774520975120. PMID: 33258687Free PMC Article
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators
Eur Urol 2021 Feb;79(2):214-221. Epub 2020 Aug 28 doi: 10.1016/j.eururo.2020.08.024. PMID: 32868138

Diagnosis

Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T, Mitsuyama K, Yamauchi R, Kakuma T, Torimura T
Kurume Med J 2023 Jul 3;68(2):43-52. Epub 2023 Apr 26 doi: 10.2739/kurumemedj.MS682006. PMID: 37100606
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.
Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, Daskalakis M, Kröger N, Dreger P, Besley C, Schanz U, Bloor A, Ganser A, Forcade E, Corral LL, Passweg JR, Novak U, Moiseev I, Schoemans H, Basak GW, Chabannon C, Sureda A, Averbuch D, Glass B, de la Camara R, Peric Z
J Immunother Cancer 2023 Apr;11(4) doi: 10.1136/jitc-2022-006406. PMID: 37072350Free PMC Article
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC
Clin Trials 2021 Feb;18(1):104-114. Epub 2020 Dec 1 doi: 10.1177/1740774520975120. PMID: 33258687Free PMC Article
Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC, McCrary JM, Park SB, Trinh T, Goldstein D
Support Care Cancer 2019 Dec;27(12):4771-4777. Epub 2019 Apr 10 doi: 10.1007/s00520-019-04781-6. PMID: 30972648
Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A, Modi M, Prakash G, Malhotra P, Khadwal A, Jain S, Kumari S, Varma N, Varma S
Clin Lymphoma Myeloma Leuk 2017 Aug;17(8):513-519.e1. Epub 2017 Jul 6 doi: 10.1016/j.clml.2017.06.035. PMID: 28842138

Therapy

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.
Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ
Lancet Oncol 2022 Dec;23(12):1547-1557. Epub 2022 Nov 4 doi: 10.1016/S1470-2045(22)00638-6. PMID: 36343656Free PMC Article
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ
Eur J Cancer 2022 Nov;175:204-213. Epub 2022 Sep 20 doi: 10.1016/j.ejca.2022.08.024. PMID: 36148739
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM, Steinberg RL, Martin AC, Richards J, Mott SL, Gellhaus PT, Nepple KG, O'Donnell MA, Packiam VT
J Urol 2022 Sep;208(3):589-599. Epub 2022 Jul 27 doi: 10.1097/JU.0000000000002740. PMID: 35892270
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC
Clin Trials 2021 Feb;18(1):104-114. Epub 2020 Dec 1 doi: 10.1177/1740774520975120. PMID: 33258687Free PMC Article
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators
Eur Urol 2021 Feb;79(2):214-221. Epub 2020 Aug 28 doi: 10.1016/j.eururo.2020.08.024. PMID: 32868138

Prognosis

Symptomatic adverse events of chemotherapy in breast cancer patients:Using CTCAE, PRO-CTCAE, and EORTC QLQ-C30.
Arahori H, Kondo K, Imai Y, Bando T, Inoue H, Sasa S, Takizawa H
J Med Invest 2024;71(1.2):82-91. doi: 10.2152/jmi.71.82. PMID: 38735729
Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T, Mitsuyama K, Yamauchi R, Kakuma T, Torimura T
Kurume Med J 2023 Jul 3;68(2):43-52. Epub 2023 Apr 26 doi: 10.2739/kurumemedj.MS682006. PMID: 37100606
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ
Eur J Cancer 2022 Nov;175:204-213. Epub 2022 Sep 20 doi: 10.1016/j.ejca.2022.08.024. PMID: 36148739
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM, Steinberg RL, Martin AC, Richards J, Mott SL, Gellhaus PT, Nepple KG, O'Donnell MA, Packiam VT
J Urol 2022 Sep;208(3):589-599. Epub 2022 Jul 27 doi: 10.1097/JU.0000000000002740. PMID: 35892270
The impact of sarcopenia on adverse events associated with gastric endoscopic submucosal dissection.
Hisada H, Tamura N, Tsuji Y, Nagao S, Fukagawa K, Miura Y, Mizutani H, Ohki D, Yakabi S, Minatsuki C, Takahashi Y, Sakaguchi Y, Yamamichi N, Fujishiro M
Surg Endosc 2022 Sep;36(9):6387-6395. Epub 2022 Jan 7 doi: 10.1007/s00464-021-08965-2. PMID: 34997343

Clinical prediction guides

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ
Eur J Cancer 2022 Nov;175:204-213. Epub 2022 Sep 20 doi: 10.1016/j.ejca.2022.08.024. PMID: 36148739
Germline genetic biomarkers to stratify patients for personalized radiation treatment.
Deichaite I, Hopper A, Krockenberger L, Sears TJ, Sutton L, Ray X, Sharabi A, Navon A, Sanghvi P, Carter H, Moiseenko V
J Transl Med 2022 Aug 12;20(1):360. doi: 10.1186/s12967-022-03561-x. PMID: 35962345Free PMC Article
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC
Clin Trials 2021 Feb;18(1):104-114. Epub 2020 Dec 1 doi: 10.1177/1740774520975120. PMID: 33258687Free PMC Article
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators
Eur Urol 2021 Feb;79(2):214-221. Epub 2020 Aug 28 doi: 10.1016/j.eururo.2020.08.024. PMID: 32868138
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.
Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, Sarkar I, Molinero L, Grossman W, Kabbinavar F, Fassò M, O'Hear C, Powderly J
Ann Oncol 2018 Nov 1;29(11):2247-2253. doi: 10.1093/annonc/mdy411. PMID: 30219915

Recent systematic reviews

Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T, Mitsuyama K, Yamauchi R, Kakuma T, Torimura T
Kurume Med J 2023 Jul 3;68(2):43-52. Epub 2023 Apr 26 doi: 10.2739/kurumemedj.MS682006. PMID: 37100606
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V
Cochrane Database Syst Rev 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3. PMID: 33930176Free PMC Article
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V
Cochrane Database Syst Rev 2020 Dec 14;12(12):CD013257. doi: 10.1002/14651858.CD013257.pub2. PMID: 33316104Free PMC Article
Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis.
Wardill HR, Van Sebille YZA, Ciorba MA, Bowen JM
Curr Opin Support Palliat Care 2018 Jun;12(2):187-197. doi: 10.1097/SPC.0000000000000338. PMID: 29547491
Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH
Eur J Cancer 2015 Nov;51(16):2314-20. Epub 2015 Sep 3 doi: 10.1016/j.ejca.2015.07.031. PMID: 26343314

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...